Ixazomib - lenalidomide - dexamethason in heavily pretreated multiple myeloma patients - case reports.

Abstract

Background: The treatment of aggressive multiple myeloma (MM) patients, resistant to several treatment modalities, is very difficult in the real-world-evidence conditions. Ixazomib is a second-generation oral proteasome inhibitor. In combination with lenalidomide and dexamethasone, it is an effective and low-toxic treatment regimen for patients with relapsed or refractory MM.

Observation: The presented case reports of two patients with an aggressive course of MM demonstrate the surprising effectiveness of this regimen.

Conclusion: Repeated treatment with a combination of proteasome inhibitors (ixazomib) and immunomodulatory drugs (lenalidomide) may lead to significant clinical benefit in some patients and should be considered even in end-stage disease patients.